DOCS— AI Stock Forecast & Price Targets
Published 7/17/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live DOCS price forecast →
Doximity is a high-quality digital health platform (89% gross margin, 30% net margin, net cash, ~$255M FCF) that has been cut in half from its 52-week high of $76.51 to $22.21, now trading at ~14x forward EPS with 15.5% short interest and earnings ~20 days out. The setup is a mean-reversion candidate off the base near $20, but Q4 FY26 revenue/margin step-down (op margin collapsing from ~38% to ~17% Q/Q, EPS Q/Q -68%) and a deteriorating tape argue for a small, disciplined position, not a hero trade into the August 6 print.
Into the August 6 earnings print, keep this small — this is a binary event with implied vol likely to crush post-report. Tactical range: accumulate a starter (¼ to ⅓ of intended position) between $20.50-$21.50 with a hard invalidation on a daily close below $19.50 (breaks the base). Upside pre-print scalp target $23.50-$24.50 (analyst PT $24.26 and prior swing high). Do NOT add into the print; earnings ARE the invalidation. If the print misses on billings or margin guide, expect a retest of $18; if it beats and Ask/Scribe attach rates surprise, $26-28 gap is realistic given 15.5% short float.
1-6 month view: constructive if management can show operating margin re-expansion back toward 30%+ and reaccelerating pharma-manufacturer ad demand. Base case is a rerating to ~17-18x forward EPS on stabilizing $1.60+ EPS, implying $27-30. Expected return range from $22.21: -15% to +35%. Key catalysts: Aug 6 print + guide, subsequent Ask/Scribe monetization datapoints, any large health-system enterprise wins. What changes my mind: second consecutive quarter of >20% sequential op-margin compression, or explicit pharma-ad softness in the guide — that would break the quality thesis and open $17-18.
1-3 year view: Doximity remains a near-monopoly professional network for U.S. physicians (>80% penetration) with structurally attractive unit economics; if AI workflow tools (Ask, Scribe, AMiON) become embedded in clinical workflow they can drive a durable second act of revenue growth beyond the mature pharma-ad core. At 89% gross margin and net cash, patient holders should compound with the FCF. Biggest structural risks: (1) OpenEvidence and frontier-model competitors commoditize clinical AI faster than Doximity can monetize; (2) pharma-manufacturer marketing budgets structurally shrink or shift channel; (3) the 2021-2023 disclosure issues reflect a governance/reporting culture that could resurface. Fair long-term terminal value if execution holds: $35-45; if the AI narrative is captured by others, sub-$20 stays the ceiling.
Business quality remains elite: TTM revenue $644.9M with 89.1% gross margin, 30.4% net margin, 19.3% ROE, 20.5% ROIC and $255M FCF against just $10.2M of debt and $748M cash — a fortress balance sheet (current ratio 6.09, debt/equity effectively 0.01). The problem is the trajectory: quarterly operating income collapsed from $71.9M in Dec-25 to $24.8M in Mar-26 while revenue fell from $185M to $145M sequentially, and reported EPS Q/Q is -68.15%. Sales Y/Y TTM is still +13% and next-year EPS growth is only +11%, so the growth premium that once justified a 40-70x multiple has evaporated. Trailing P/E 22.6x and forward 13.9x with EV/EBITDA 14x are reasonable for the quality, but PEG 2.0 and P/S 6.3x say this is priced like a slowing SaaS name, not a bargain. Capital allocation looks fine (no dividend, FCF conversion strong, buybacks implied by share count stability), but the market clearly wants proof that the Q4 weakness was seasonal/one-off, not a structural pharma-ad demand issue.
Across timeframes, DOCS is trying to base after a violent multi-quarter downtrend. Weekly chart shows a peak near $102 and a drop to a $20 floor tested repeatedly since April — classic capitulation-then-consolidation shape, with price sitting +3.9% above the 20-DMA and +3.5% above the 50-DMA but still -38.8% below the 200-DMA, so the long-term trend is not healed. The 1h and 4h charts show a clean bounce off the $20 shelf into the $22-23 zone; RSI(14) at 55 is neutral-constructive, and Perf Month +7.4% confirms accumulation. Resistance is stacked: $23 (July high), then $26-27 (May pivot), then $29-30 (April supply). Support is $21 then the critical $19.80-20.20 base — a weekly close below $19.50 breaks the structure. The model's short-horizon forecast band on the 1h/4h ($21.5-$26.8) is directionally plausible, but the 1d/1wk forecasts of $44 and $35 are wildly out of line with realized 33% directional accuracy on the weekly (worse than a coin flip / naive baseline of 83%), so those upside prints should be heavily discounted. 15.5% short float on a name with 70% institutional ownership sets up squeeze potential, but only on a positive catalyst.
Signal: the July 15 Stanford/Harvard NOHARM benchmark result showing Doximity Ask beat OpenEvidence and frontier models on clinical AI safety is a legitimate product differentiator in the healthcare AI narrative, and management has scheduled the FY27 Q1 print for August 6 after close — the real catalyst. Noise: the Zacks/Yahoo daily-move recap and the 'Winners and Losers of Q1' round-up are backward-looking. Broader-market items (crypto prediction markets, CLARITY Act, unrelated M&A) are irrelevant to DOCS. Social sentiment is dominated by pump-group spam and a reminder about a $31M securities-class-action settlement claim deadline — the settlement itself is already known and priced in, but it underscores the 2021-2023 disclosure overhang.
- Doximity Ask outperformed OpenEvidence and frontier LLMs on the Stanford-Harvard NOHARM clinical-AI-safety benchmark (July 15, 2026) — enterprise selling point for HIPAA-compliant clinical AI
- Scribe (AI clinical documentation) monetization ramp as ambient-scribe becomes standard-of-care in U.S. health systems
- AMiON scheduling tool as land-and-expand wedge into hospital workflow beyond the individual physician
- Pharma-manufacturer digital ad share recovery — historically 80%+ of revenue and the main lever for op-margin re-expansion back toward 30%+
- Attach rate expansion of workflow tools across the ~80% penetrated U.S. physician base — modest ARPU lift compounds given fixed member acquisition
- Aug 6 earnings is a binary event; Q4 FY26 already showed op margin dropping from 38.9% to 17.1% Q/Q and EPS Q/Q -68% — a second soft print resets the multiple
- 15.5% short float / 4.8 short ratio signals meaningful bearish institutional positioning that has been correct year-to-date (Perf YTD -49.8%, Perf Year -64.4%)
- Valuation is no longer cheap on growth: PEG 2.0, EPS next-5Y only 6.9%, forward P/E 13.9x — limited multiple expansion without a growth reacceleration
- Competitive threat from OpenEvidence and general-purpose frontier models commoditizing clinical AI despite the NOHARM win
- Pharma-marketing budget cyclicality/secular pressure — revenue concentration in pharma-manufacturer ads is the single biggest swing factor
- Legacy disclosure overhang: $31M securities-class-action settlement (2021-2023 period) reflects prior reporting issues and residual governance risk
- Model's own 1d/1wk forecasts ($44 / $35) have realized directional accuracy below the naive baseline — do not underwrite the bullish AI forecast
- Macro backdrop is risk-off (composite +2, breadth deteriorating) — small caps and unprofitable-narrative names historically underperform in this regime
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord